622 related articles for article (PubMed ID: 34221187)
1. Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response.
Jiang H; Ning G; Wang Y; Lv W
Dis Markers; 2021; 2021():5576683. PubMed ID: 34221187
[TBL] [Abstract][Full Text] [Related]
2. m6A-Related Genes Contribute to Poor Prognosis of Hepatocellular Carcinoma.
Zou Y; Jiang G; Xie Y; Li H
Comput Math Methods Med; 2022; 2022():2427987. PubMed ID: 36339682
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
4. Ahypoxia-related signature enhances the prediction of the prognosis in hepatocellular carcinoma patients and correlates with sorafenib treatment response.
Jiang HY; Ning G; Wang YS; Lv WB
Am J Transl Res; 2020; 12(12):7762-7781. PubMed ID: 33437359
[TBL] [Abstract][Full Text] [Related]
5. Multiple m
Qu N; Qin S; Zhang X; Bo X; Liu Z; Tan C; Wen G; Jiang H
BMC Cancer; 2020 Feb; 20(1):165. PubMed ID: 32111180
[TBL] [Abstract][Full Text] [Related]
6. The m6A methylation landscape stratifies hepatocellular carcinoma into 3 subtypes with distinct metabolic characteristics.
Shen X; Hu B; Xu J; Qin W; Fu Y; Wang S; Dong Q; Qin L
Cancer Biol Med; 2020 Nov; 17(4):937-952. PubMed ID: 33299645
[TBL] [Abstract][Full Text] [Related]
7. The potential role of RNA N6-methyladenosine in primary Sjögren's syndrome.
Xiao Q; Wu X; Deng C; Zhao L; Peng L; Zhou J; Zhang W; Zhao Y; Fei Y
Front Med (Lausanne); 2022; 9():959388. PubMed ID: 36465909
[TBL] [Abstract][Full Text] [Related]
8. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
Li L; Xie R; Lu G
Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
[TBL] [Abstract][Full Text] [Related]
9. m
Li W; Liu J; Ma Z; Zhai X; Cheng B; Zhao H
Dis Markers; 2021; 2021():8859590. PubMed ID: 34234878
[TBL] [Abstract][Full Text] [Related]
10. Identification of METTL3 as an Adverse Prognostic Biomarker in Hepatocellular Carcinoma.
Liu GM; Zeng HD; Zhang CY; Xu JW
Dig Dis Sci; 2021 Apr; 66(4):1110-1126. PubMed ID: 32333311
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of an m6A RNA Methylation Regulator-Based Signature in Patients with Hepatocellular Carcinoma.
Wu X; Zhang X; Tao L; Dai X; Chen P
Biomed Res Int; 2020; 2020():2053902. PubMed ID: 32733931
[TBL] [Abstract][Full Text] [Related]
12. The identification of N6-methyladenosine-related miRNAs predictive of hepatocellular carcinoma prognosis and immunotherapy efficacy.
Zou R; Liu Y; Qiu S; Lu Y; Chen Y; Yu H; Zhu H; Zhu W; Zhu L; Feng J; Han J
Cancer Biomark; 2023; 38(4):551-566. PubMed ID: 38007640
[TBL] [Abstract][Full Text] [Related]
13. The significance of m6A RNA methylation regulators in predicting the prognosis and clinical course of HBV-related hepatocellular carcinoma.
Fang Q; Chen H
Mol Med; 2020 Jun; 26(1):60. PubMed ID: 32552682
[TBL] [Abstract][Full Text] [Related]
14. The Cancer Genome Atlas (TCGA) based m
Liu J; Sun G; Pan S; Qin M; Ouyang R; Li Z; Huang J
Bioengineered; 2020 Dec; 11(1):759-768. PubMed ID: 32631107
[TBL] [Abstract][Full Text] [Related]
15. Bioinformatic analyses and experimental validation of the role of m6A RNA methylation regulators in progression and prognosis of adrenocortical carcinoma.
Xu F; Guan Y; Ma Y; Xue L; Zhang P; Yang X; Chong T
Aging (Albany NY); 2021 Apr; 13(8):11919-11941. PubMed ID: 33952721
[TBL] [Abstract][Full Text] [Related]
16. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.
Feng NN; Du XY; Zhang YS; Jiao ZK; Wu XH; Yang BM
Front Endocrinol (Lausanne); 2022; 13():1061091. PubMed ID: 36714595
[TBL] [Abstract][Full Text] [Related]
17. Identification of PANoptosis-Based Prognostic Signature for Predicting Efficacy of Immunotherapy and Chemotherapy in Hepatocellular Carcinoma.
Xiong X; Song Q; Jing M; Yan W
Genet Res (Camb); 2023; 2023():6879022. PubMed ID: 37313428
[TBL] [Abstract][Full Text] [Related]
18. N6-Methyladenosine RNA Methylation Regulator-Related Alternative Splicing (AS) Gene Signature Predicts Non-Small Cell Lung Cancer Prognosis.
Zhao Z; Cai Q; Zhang P; He B; Peng X; Tu G; Peng W; Wang L; Yu F; Wang X
Front Mol Biosci; 2021; 8():657087. PubMed ID: 34179079
[TBL] [Abstract][Full Text] [Related]
19. Quantification of m6A RNA methylation modulators pattern was a potential biomarker for prognosis and associated with tumor immune microenvironment of pancreatic adenocarcinoma.
Wang L; Zhang S; Li H; Xu Y; Wu Q; Shen J; Li T; Xu Y
BMC Cancer; 2021 Jul; 21(1):876. PubMed ID: 34332578
[TBL] [Abstract][Full Text] [Related]
20. Expression and Prognostic Significance of m6A-Related Genes in Lung Adenocarcinoma.
Zhang Y; Liu X; Liu L; Li J; Hu Q; Sun R
Med Sci Monit; 2020 Feb; 26():e919644. PubMed ID: 32086933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
